Simplified Chinese
Core pipeline in development
The company holds patents.90Remaining items, with nearly … varieties under development.30Item, including projects that have entered the registration process.18item
Product Name
Preclinical
Phase I clinical trial
Phase II clinical trial
Phase III clinical trial
NDA
Quadrivalent Influenza Virus Split Vaccine (for individuals aged 3 years and older)
NDA
Adsorbed tetanus vaccine
NDA
Trivalent Influenza Virus Split Vaccine (for individuals aged 3 years and older)
NDA
Oral pentavalent reassortant live attenuated rotavirus vaccine (Vero cells)
Phase III clinical trial
Adsorbed Diphtheria–Tetanus–Pertussis (Component) Combined Vaccine (Infants and Young Children)
Phase I clinical trials have been completed, and the product is currently in Phase III clinical trials.
20-valent pneumococcal polysaccharide conjugate vaccine
Phase II clinical trial
Adsorbed acellular diphtheria–tetanus–pertussis, inactivated poliovirus, and Haemophilus influenzae type b combined vaccine (pentavalent vaccine)
About to enter Phase III clinical trials.
Adsorbed Diphtheria–Tetanus–Pertussis Inactivated Poliovirus Combined Vaccine
Phase I clinical trial
Measles-Mumps-Rubella Combined Attenuated Live Vaccine
Phase I clinical trial
Quadrivalent Inactivated Enterovirus Vaccine (EV-A71/CV-A6/CV-A10/CV-A16) (Vero Cell)
Phase I clinical trial
Quadrivalent Influenza Virus Split Vaccine (for infants aged 6–35 months)
Approved for clinical trials
Quadrivalent Influenza Virus Split Vaccine (MDCK Cells)
Approved for clinical trials
24-valent pneumococcal polysaccharide conjugate vaccine
Preclinical
Combined attenuated live vaccine for measles, mumps, rubella, and varicella
Preclinical
Shingles vaccine
Preclinical
Respiratory Syncytial Virus Vaccine (RSV)
Preclinical
Combined vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)
Preclinical
Klebsiella pneumoniae vaccine
Preclinical